Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: A rapid test for reversibility of pulmonary hypertension

被引:77
作者
Givertz, MM
Hare, JM
Loh, E
Gauthier, DF
Colucci, WS
机构
[1] HARVARD UNIV,SCH MED,BOSTON MED CTR,CARDIOMYOPATHY PROGRAM,BOSTON,MA 02118
[2] HARVARD UNIV,SCH MED,BOSTON MED CTR,DIV CARDIOVASC,BOSTON,MA 02118
[3] BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115
[4] BRIGHAM & WOMENS HOSP,CARDIOMYOPATHY PROGRAM,BOSTON,MA 02115
[5] BOSTON UNIV,SCH MED,DIV CARDIOVASC,BOSTON,MA 02118
[6] BOSTON UNIV,SCH MED,CARDIOMYOPATHY PROGRAM,BOSTON,MA 02118
关键词
D O I
10.1016/S0735-1097(96)00399-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To examine the feasibility of using milrinone to test pulmonary vascular reactivity in patients before heart transplantation, we tested the hypothesis that milrinone would lower pulmonary vascular resistance (PVR) in patients with severe heart failure, Background Fixed pulmonary hypertension is a risk factor for right heart failure and death after orthotopic heart transplantation, Sodium nitroprusside, the agent used most commonly to test for reversibility of pulmonary hypertension before transplantation, requires dose titration and is frequently limited by hypotension, Milrinone is an intravenously active phosphodiesterase inhibitor that acts rapidly and exerts both positive inotropic and direct vasodilator effects in patients with heart failure, The ability of milrinone to lower PVR in patients with heart failure has not been tested, Methods. In 27 patients with New York Heart Association functional class III or TV heart failure referred for heart transplantation with a PVR greater than or equal to 200 dynes-s-cm(-5), we measured the hemodynamic response to a single intravenous bolus of milrinone (50 mu g/kg body weight) infused over 1 min. Results. Milrinone decreased PVR in all patients, The effect was maximal 5 to 10 min after the bolus and persisted for at least 20 min, The reduction in PVR at 5 min ([mean +/- SEM] 31 +/- 4%) was associated with a 42 +/- 4% increase in cardiac output and decreases of 12 +/- 4% and 16 +/- 5% in mean pulmonary artery and pulmonary artery wedge pressures, respectively, but no change in transpulmonary pressure gradient, Milrinone had no effect on heart rate or systemic arterial pressure, The magnitude of the decrease in PVR correlated inversely with the milrinone-induced increase in cardiac output. Conclusions. Bolus milrinone consistently decreases PVR in patients with pulmonary hypertension secondary to severe heart failure, This effect is rapid in onset and well tolerated, even by patients with low systemic arterial pressure, An intravenous bolus of milrinone can be used to test for the reversibility of pulmonary hypertension in patients with heart failure undergoing evaluation for heart transplantation. (C) 1996 by the American College of Cardiology
引用
收藏
页码:1775 / 1780
页数:6
相关论文
共 34 条
[1]   INHALED NITRIC-OXIDE AND HEMODYNAMIC EVALUATION OF PATIENTS WITH PULMONARY-HYPERTENSION BEFORE TRANSPLANTATION [J].
ADATIA, I ;
PERRY, S ;
LANDZBERG, M ;
MOORE, P ;
THOMPSON, JE ;
WESSEL, DL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 25 (07) :1656-1664
[2]  
ADDONIZIO LJ, 1987, CIRCULATION, V76, P52
[3]  
ALOUSI AA, 1986, CIRCULATION, V73, P10
[4]   EVALUATION OF A NEW BIPYRIDINE INOTROPIC AGENT - MILRINONE - IN PATIENTS WITH SEVERE CONGESTIVE HEART-FAILURE [J].
BAIM, DS ;
MCDOWELL, AV ;
CHERNILES, J ;
MONRAD, ES ;
PARKER, JA ;
EDELSON, J ;
BRAUNWALD, E ;
GROSSMAN, W .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (13) :748-756
[5]   EFFECTS OF INTRAVENOUS MILRINONE ON LEFT-VENTRICULAR FUNCTION IN ISCHEMIC AND IDIOPATHIC DILATED CARDIOMYOPATHY [J].
BRECKER, SJD ;
XIAO, HB ;
MBAISSOUROUM, M ;
GIBSON, DG .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (02) :203-209
[6]  
Coddens J, 1993, J Cardiothorac Vasc Anesth, V7, P321, DOI 10.1016/1053-0770(93)90013-B
[7]   IDENTIFICATION OF THE DIRECT VASODILATOR EFFECT OF MILRINONE WITH AN ISOLATED LIMB PREPARATION IN PATIENTS WITH CHRONIC CONGESTIVE-HEART-FAILURE [J].
CODY, RJ ;
MULLER, FB ;
KUBO, SH ;
RUTMAN, H ;
LEONARD, D .
CIRCULATION, 1986, 73 (01) :124-129
[8]   NEW POSITIVE INOTROPIC AGENTS IN THE TREATMENT OF CONGESTIVE-HEART-FAILURE - MECHANISMS OF ACTION AND RECENT CLINICAL DEVELOPMENTS .2. [J].
COLUCCI, WS ;
WRIGHT, RF ;
BRAUNWALD, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (06) :349-358
[9]   FLOW STIMULATES ENDOTHELIAL-CELLS TO RELEASE A NITROVASODILATOR THAT IS POTENTIATED BY REDUCED THIOL [J].
COOKE, JP ;
STAMLER, J ;
ANDON, N ;
DAVIES, PF ;
MCKINLEY, G ;
LOSCALZO, J .
AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 259 (03) :H804-H812
[10]   INFLUENCE OF PREOPERATIVE PULMONARY-ARTERY PRESSURE ON MORTALITY AFTER HEART-TRANSPLANTATION - TESTING OF POTENTIAL REVERSIBILITY OF PULMONARY-HYPERTENSION WITH NITROPRUSSIDE IS USEFUL IN DEFINING A HIGH-RISK GROUP [J].
COSTARDJACKLE, A ;
FOWLER, MB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (01) :48-54